Characteristics of Asian-American Breast Cancer Survivors Retained in a 3-Month Technology-Based Intervention.
Jee-Seon Yi, Wonshik Chee, Eun-Ok Im
PMID 34661563WHAT IT FOUND
79.4% of 155 Asian American breast cancer survivors remained in a 3-month online support program.
Stage I disease, Chinese ethnicity, older age at immigration, low loneliness and perceived barriers were linked to retention.
Key findings
01Among 155 women who completed the pretest, retention rates were 100.0% at pretest, 83.9% at 1 month and 79.4% at 3 months.
02At 3 months, 87.5% of Chinese participants and 94.7% of participants with Stage I breast cancer were retained; retained participants had an average immigration age of 36.949 years.
03In the decision tree, low loneliness raised predicted retention to 96.4% among Stage I cancer; one Chinese branch predicted 81.8% retention, and one branch with older immigration age and higher perceived barriers predicted 100.0% retention.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This was a secondary analysis of an ongoing intervention study, so the variables available were limited to what that larger study collected. Retention was analysed using pretest values, so the analysis cannot show whether the program itself affected who stayed. The paper says nobody withdrew, yet it reports later retention rates, so the meaning of dropout and retention is unclear. The supplied text does not describe randomisation, blinding, allocation or conflicts of interest for the larger study. The findings are about who stayed in a research program, not whether the program helped patients.
Declared interests
The supplied text does not include a funding or conflict-of-interest declaration. The publication types indicate NIH extramural research support.
The easy way to misread this
Do not read the decision-tree percentages as proof that the technology-based program improves breast cancer survivorship outcomes. This analysis describes who remained in a research program, not patient benefit.